Navigation Links
Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Date:5/11/2009

RM-1 trial as an oral late breaker at the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark. This is the first study to investigate the activity of a combination of two oral antiviral molecules to treat HCV in the absence of interferon. The study is investigating the combination of Pharmasset's R7128, a nucleoside inhibitor, with InterMune's R7227, a protease inhibitor;
  • On April 24, 2009, Pharmasset announced that its development partner, Roche, had initiated dosing of patients in the phase 2b trial of R7128 in combination with the standard of care in genotype 1 and 4 HCV infected patients. The start of the trial triggered a $10.0 million milestone payment to Pharmasset that is expected to be received in the quarter ending June 30, 2009;
  • On April 20, 2009, Pharmasset announced that it had voluntarily halted its phase 3 registration studies of clevudine for the treatment of chronic hepatitis B infection;
  • On March 31, 2009, Pharmasset announced the dosing of the first healthy volunteer in the phase 1 trial with PSI-7851, a second generation nucleotide inhibitor of HCV.

  • "Our HCV pipeline continues to make solid progress," stated Schaefer Price, President and Chief Executive Officer. "In April, we announced exciting data from the INFORM-1 trial at EASL and the initiation of the phase 2b trial with R7128. We are now able to increase our focus on further strengthening our portfolio of HCV nucleos(t)ides with the decision to halt registration studies with clevudine. We look forward to providing the first antiviral data on PSI-7851 in the second half of 2009."

    Calendar Year 2009 Anticipated Milestones:

    • Announce selection of candidate(s) from our purine series of nucleos(t)ide analog for HCV in second half of 2009;
    • Provide update on safety from first 100 patients in t
      '/>"/>

    SOURCE Pharmasset, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
    3. Pharmasset Accesses up to $30 Million of Working Capital
    4. Pharmasset to Present at Three Investor Conferences in November 2007
    5. Pharmasset Appoints Michael Rogers as Chief Development Officer
    6. Pharmasset Reports Fiscal Year End 2007 Financial Results
    7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
    8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
    9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
    10. Pharmasset Appoints Herbert J. Conrad as a Director
    11. Pharmasset Receives $10 Million of Working Capital
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2015)... CITY , July 28, 2015 /PRNewswire/ - Aeterna ... today announced that it has granted to German ... funding the development and commercialization of biotechnology (collectively, ... live recombinant oral allogenic tumor vaccine technology (the ... for prostate cancer which is ready to enter ...
    (Date:7/27/2015)... THOUSAND OAKS, Calif. , July 27, 2015 /PRNewswire/ ... will report its second quarter financial results on Thursday, ... financial markets. The announcement will be followed by a ... PT. Participating in the call from Amgen will be ... officer, and other members of Amgen,s senior management team. ...
    (Date:7/27/2015)... ... , ... Production of high tenacity filament yarn of viscose rayon (excluding sewing ... instance, it surpassed the EUR 106 million mark (in value terms) in 2013, while ... major producer, while Italy is a key consumer. , The high tenacity filament ...
    (Date:7/27/2015)... ... July 27, 2015 , ... ... network Monday. The venture will bring the world’s most efficient gas dissolution technology ... equipment and technologies to both the industrial and municipal markets. With offices located ...
    Breaking Biology Technology:Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2BlueInGreen Brings Water Treatment Technology to Florida 2
    ... to the anterior cruciate ligament (ACL) is fairly common, ... corrected through surgery, the injury can lead to increased ... The problem is that fluid in the knee joint, ... of the injury and begins to deteriorate. A new ...
    ... DENVER , Aug. 5 Forensic ... services for drug and alcohol abuse, has announced the ... is the first lab in the nation to develop ... in saliva, a chemical produced by the body after ...
    ... Oncimmune® (USA) LLC , provider of Early ... and the early detection of lung cancer , today announced ... the test. The study titled " Clinical Validation of an Autoantibody ... at Annals of Oncology , Oxford Journals, or at Oncimmune,s ...
    Cached Biology Technology:Lubricating the knee cartilage after ACL injury may prevent osteoarthritis 2Lubricating the knee cartilage after ACL injury may prevent osteoarthritis 3Forensic Laboratories Develops First Oral Fluid Test for Ethyl Sulfate Detection 2New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 2New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 3New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 4New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 5New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 6
    (Date:7/21/2015)... Sweden , July 21, 2015 Today, ... FPC1025. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
    (Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
    (Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
    Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
    ... postmenopausal women and people of all ages, actually ... solution to help prevent fractures and osteoporosis: eating dried plums. ... figs, dates, strawberries and raisins, and none of them come ... dried plums, or prunes, have," said Bahram H. Arjmandi, Florida ...
    ... cloud computing becomes the next big consumer techo trend, ... physically store everything from playlists to photos, it,s ... is done. Using the cloud model as inspiration, biomedical ... the Translational Research Informatics and Data management grid (TRIAD), ...
    ... partnering organizations have discovered a remarkably primitive eel in a ... This fish exhibits many primitive anatomical features unknown in the ... eels, resulting in its classification as a new species belonging ... published online in the Proceedings of the Royal Society ...
    Cached Biology News:No bones about it: Eating dried plums helps prevent fractures and osteoporosis 2Biomedical research gets its head into cloud computing 2Biomedical research gets its head into cloud computing 3Biomedical research gets its head into cloud computing 4Scientists discover the most primitive living eel 2
    RAT ANTI MOUSE METALLOPHILIC MACROPHAGES...
    ... Ferrofluid products perform optimally when ... Systems MagCellect Magnet. To accommodate ... iron boron permanent magnet holds ... mm test tubes or two ...
    Request Info...
    Form: Concentrated Applications: ELISA...
    Biology Products: